Regenerative potential of platelets in patients with chronic kidney disease
- 25 Downloads
Chronic kidney disease (CKD) is a systemic disease affecting many organs. Progression of renal failure aggravates ongoing inflammation and increases oxidative stress. In the final stage of CKD, it is necessary to use renal replacement therapy. A side effect of dialysis therapy is the synthesis of proinflammatory factors and increased oxidative stress, which activates platelets and immune cells.
Aim of the study
To determine the regenerative potential of platelets in patients with CKD based on the analysis of the relationships between substances with potential regenerative action, as well as analysis of the influence of the type of renal replacement therapy used on regeneration of platelets.
Materials and methods
The study group consisted of 117 patients. Based on the type of therapy used, patients were divided into four groups: hemodialysis, peritoneal dialysis, kidney transplant patients, and conservative treatment (30, 30, 27, and 30 patients). The control group consisted of 30 healthy volunteers. The concentrations of IGF-1, TGF-β, and PDGF-B in the blood serum were measured by ELISA methods.
It was shown that renal replacement therapy significantly influences the concentration of platelet growth factors (IGF-1: p = 0.025 and PDGF-B: p = 0.012). There was a relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of IGF-1, PDGF-B (p < 0.00001, p < 0.001).
The type of renal replacement therapy has a different effect on the concentration of platelet-derived growth factors IGF-1 and PDGF-B. PD patients had the highest concentrations of all growth factors, and this may be due to the presence of inflammation induced by dialysis-related advanced end-products of glycosylation (AGE).
KeywordsPlatelet growth factors IGF-1 PDGF-B TGF-β Chronic kidney disease
This paper was funded by NCN 2011/01/B/NZ5/04235 and by Pomeranian Medical University no. MB-134-141/15.
- 6.Antoniades HN, Williams LT (1983) Human platelet-derived growth factor: structure and function. Feder Proc 42:2630–2634Google Scholar
- 10.Betsholtz C (1995) Role of platelet-derived growth factors in mouse development. Int J Dev Biol 39:817–825Google Scholar
- 15.Border WA, Okuda S, Nakamura T, Languino LR, Ruoslahti E (1991) Role of TGF-beta 1 in experimental glomerulonephritis. Ciba Found Symp 157:178–189Google Scholar
- 17.Ziyadeh FN (1994) Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol 2:137Google Scholar
- 25.Nicolini D, Mocchegiani F, Palmonella G, Coletta M, Brugia M et al (2015) Postoperative insulin-like growth factor 1 levels reflect the graft’s function and predict survival after liver transplantation. PLoS One 17:10Google Scholar
- 29.Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller B (1997) Insulin-like growth factor I preserves renal function postoperatively. Am J Physiol 272:F257–F259Google Scholar
- 30.Vijayan A, Franklin SC, Behrend T, Hammerman MR, Miller B (1999) Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am J Physiol 276:R929–R934Google Scholar
- 39.Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020CrossRefGoogle Scholar
- 41.Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90(1814–1818):12Google Scholar
- 43.Mekki K, Taleb W, Biuzidi N, Kaddous A, Bouchenak M (2010) Effect of hemodialysis and peritoneal dialysis on redox status in chronić renal failure patients: a comparative study. Lipids Health Dis 2010:9–93Google Scholar